ORIC PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
ORIC PHARMACEUTICALS, INC. (ORIC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $8.39 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $8.48, a 23.80% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $6.85, a 10.31% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $6.21, a 15.64% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $5.37, a 69.95% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $7.90, a 20.06% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $6.58, a 24.62% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $5.28, a 67.86% decline from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $16.43, a 21.84% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.39 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $8.48 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $7.90 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $7.82 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $8.60 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $6.85 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $6.58 10-K · filed 2025-02-18 | |||
| 2024-09-30 | $6.57 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $6.45 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $6.21 10-Q · filed 2024-05-06 | |||
| 2023-12-31 | $5.28 10-K · filed 2024-03-11 | |||
| 2023-09-30 | $4.97 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $5.21 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $5.37 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $16.43 10-K · filed 2023-03-16 | |||
| 2022-09-30 | $16.52 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $16.94 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $17.87 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $21.02 10-K · filed 2022-03-21 | |||
| 2021-09-30 | $21.20 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $22.92 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $19.06 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $12.96 10-K · filed 2021-03-23 | |||
| 2020-09-30 | $7.39 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $3.05 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | $1.60 10-Q · filed 2020-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |